GNII.F Stock Overview

Engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. More details

GNII.F fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	5/6
Past Performance	4/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings are forecast to grow 23.87% per year

Earnings grew by 371.2% over the past year

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

My Notes

Capture your thoughts, links and company narrative

GNI Group Ltd. Competitors

MiMedx Group

NasdaqCM:MDXG

US$1.3b

ACADIA Pharmaceuticals

NasdaqGS:ACAD

US$2.8b

MannKind

NasdaqGM:MNKD

US$1.9b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

Price History & Performance

Summary of share price highs, lows and changes for GNI Group
Historical stock prices
Current Share Price	JP¥19.88
52 Week High	JP¥21.81
52 Week Low	JP¥19.88
Beta	1.3
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	270.90%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	GNII.F	US Biotechs	US Market
7D	0%	-3.6%	-2.4%
1Y	n/a	-2.6%	23.4%

Return vs Industry: Insufficient data to determine how GNII.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how GNII.F performed against the US Market.

Price Volatility

Is GNII.F's price volatile compared to industry and market?
GNII.F volatility
GNII.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: GNII.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine GNII.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	843	Ying Luo	www.gnipharma.com

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy.

GNI Group Ltd. Fundamentals Summary

How do GNI Group's earnings and revenue compare to its market cap?
GNII.F fundamental statistics
Market cap	US$1.03b
Earnings (TTM)	US$45.96m
Revenue (TTM)	US$144.89m

22.4x

P/E Ratio

7.1x

P/S Ratio

Is GNII.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNII.F income statement (TTM)
Revenue	JP¥22.65b
Cost of Revenue	JP¥4.73b
Gross Profit	JP¥17.93b
Other Expenses	JP¥10.74b
Earnings	JP¥7.19b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	143.40
Gross Margin	79.14%
Net Profit Margin	31.72%
Debt/Equity Ratio	17.5%

How did GNII.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 00:41
End of Day Share Price	2024/12/13 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GNI Group Ltd. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Stephen Barker	Jefferies LLC
Yuriko Ishida	Mizuho Securities Co., Ltd.
Nia Dokova	Pelham Smithers Associates Ltd.